Zoetis Inc. (NYSE:ZTS) Stock Holdings Lessened by OLD Second National Bank of Aurora

OLD Second National Bank of Aurora lowered its stake in Zoetis Inc. (NYSE:ZTS) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,829 shares of the company’s stock after selling 287 shares during the period. OLD Second National Bank of Aurora’s holdings in Zoetis were worth $2,335,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Blue Bell Private Wealth Management LLC lifted its position in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after acquiring an additional 89 shares during the last quarter. Evermay Wealth Management LLC lifted its holdings in Zoetis by 439.3% in the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after buying an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares during the period. Worth Asset Management LLC acquired a new stake in Zoetis in the first quarter worth $26,000. Finally, Moisand Fitzgerald Tamayo LLC raised its holdings in Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.9 %

Zoetis stock traded up $1.33 during mid-day trading on Thursday, reaching $152.84. The stock had a trading volume of 1,304,234 shares, compared to its average volume of 2,941,219. The company has a market capitalization of $69.90 billion, a price-to-earnings ratio of 30.15, a PEG ratio of 2.34 and a beta of 0.85. The company has a 50-day moving average price of $177.35 and a two-hundred day moving average price of $180.39. Zoetis Inc. has a one year low of $148.48 and a one year high of $201.92. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. Zoetis’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 EPS. On average, analysts expect that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Barclays lifted their price objective on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Wednesday, February 14th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a report on Tuesday. The Goldman Sachs Group boosted their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Stifel Nicolaus lowered their price objective on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and an average price target of $221.75.

Insider Activity

In related news, EVP Roxanne Lagano sold 363 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total value of $71,779.62. Following the completion of the sale, the executive vice president now directly owns 20,417 shares in the company, valued at $4,037,257.58. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.12% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.